Podcasts

Recent Episodes

September 4, 2026

Current Approaches and Future Directions for Early-Stage TNBC

September 1, 2026

A Breast Radiologist Breaks Down Breast Cancer Screening Guidelines: With Sara Nunnery, MD, MSCI; and Dana Bonaminio, MD

August 31, 2026

Non–Small Cell Lung Cancer 2026 UPDATE

Michael K. Wong, MD, Roswell Park Comprehensive Cancer Center

August 28, 2026

FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC

Eric D. Whitman, MD, and Francis Paul Worden, MD, discuss the integration of immunotherapy into the CSCC treatment paradigm.

August 28, 2026

Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD

$Sagar Lonial, MD, FACP, FASCO, shares the significance of the FDA approval of iberdomide/daratumumab/dexamethasone in replased/refractory multiple myeloma.$

August 27, 2026

FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

August 24, 2026

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

August 21, 2026

Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD

August 20, 2026

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

Sara Nunnery, MD, MSCI; Eleonora Teplinsky, MD

August 18, 2026

Breast Cancer Endocrine Therapy Profiles Prompt Individualized Toxicity Management Conversations: With Sara Nunnery, MD, MSCI; and Eleonora Teplinsky, MD

All series

All Podcasts

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

July 21st 2026

OncLive On Air® CE

DLBCL 2026 UPDATE

BySamantha A. Armstrong, MD,Karine Tawagi, MD

July 20th 2026

Two Onc Docs delivers a comprehensive, board-focused review of DLBCL for 2026, updating their prior coverage to reflect several recent practice changes.

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

July 20th 2026

OncLive On Air® CE

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

July 17th 2026

OncLive On Air® CE

Neil D. Gross, MD, FACS, The University of Texas MD Anderson Cancer Center

Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

ByNeil D. Gross, MD, FACS

July 17th 2026

Dr Gross discusses the key biological and clinical distinctions between cutaneous squamous cell carcinoma and basal cell carcinoma.

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

July 16th 2026

OncLive On Air® CE

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

July 15th 2026

OncLive On Air® CE

Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

July 14th 2026

OncLive On Air® CE

RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

ByGerald Soff, MD

July 13th 2026

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

July 13th 2026

OncLive On Air® CE

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

July 10th 2026

OncLive On Air® CE

FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD

ByAlex Herrera, MD

July 9th 2026

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for untreated classical Hodgkin lymphoma.

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

July 9th 2026

OncLive On Air® CE

D. Ross Camidge, MD, PhD; Funda Meric-Bernstam, MD, department chair, Endowed Nellie B. Connally Chair in Breast Cancer, Department of Investigational Cancer Therapeutics, medical director, Khalifa Institute for Personalized Cancer Therapy, professor, breast surgical oncology, The University of Texas MD Anderson Cancer Center in Houston, regular member, Cancer Biology, University of Texas Houston Graduate School of Biomedical Sciences

How a Passion for Translational Research Fuses Surgery, Science, and Phase 1 Drug Development: With D. Ross Camidge, MD, PhD; and Funda Meric-Bernstam, MD

ByRoss Camidge, MD, PhD,Funda Meric-Bernstam, MD

July 8th 2026

This episode highlights Dr Meric-Bernstam's evolution from a science-focused student into a leader in precision oncology and early-phase drug development.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; MinhTri Nguyen, MD, breast medical oncologist, assistant professor, lead faculty for Health Equity, Rush MD Anderson Cancer Center

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

BySara Nunnery, MD, MSCI,MinhTri Nguyen, MD

July 7th 2026

Drs Nunnery and Nguyen discuss the emergence of the oral SERD giredestrant in hormone receptor–positive, HER2-negative breast cancer management.

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

July 7th 2026

OncLive On Air® CE

FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

ByCharles E. Geyer, MD

June 30th 2026

Charles E. Geyer, MD, discusses the FDA approvals of trastuzumab deruxtecan for the management of early-stage HER2-positive breast cancer.

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

ByClaire Harrison, MD

June 30th 2026

Claire Harrison, MD, discusses data for luspatercept in myelofibrosis-associated anemia from the INDEPENDENCE trial.

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

BySara Nunnery, MD, MSCI,Megan Kruse, MD

June 30th 2026

Drs Nunnery and Kruse discuss the controversy surrounding a biomarker-driven switch strategy in hormone receptor–positive, HER2-negative breast cancer.

Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma

June 30th 2026

OncLive On Air® CE

Martin Schoen, MD, and Andrew W. Hahn, MD

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

ByMartin W. Schoen, MD, MPH,Andrew W. Hahn, MD

June 30th 2026

Martin Schoen, MD, and Andrew W. Hahn, MD, discuss ARPI use in elderly, frail, and high-comorbidity patients with mCSPC

David O’Malley, MD, The Ohio State University Comprehensive Cancer Center–James

Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD

ByDavid O'Malley, MD

June 30th 2026

Dr O’Malley discusses his approach to treatment selection and sequencing in platinum-resistant ovarian cancer.

Unlocking the Power of ctDNA for Residual Disease, Resistance Monitoring, and Real-Time Treatment Decisions in GI Cancers: With Christopher Lieu, MD

ByChristopher Lieu, MD

June 29th 2026

Christopher Lieu, MD, discusses the evolving clinical role of ctDNA in GI oncology, including MRD-guided treatment decisions and liquid biopsy vs tissue testing in mCRC.

FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE

ByCourtney DiNardo, MD, MSCE

June 29th 2026

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine and cedazuridine plus venetoclax in acute myeloid leukemia.

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

June 26th 2026

OncLive On Air® CE

Quadruplet Regimens and T-Cell Redirection Are on the Map of Myeloma Management Strategies: With Chandler Park, MD; Muhamed Baljevic, MD, FACP

ByChandler Park, MD, MSc, FACP,Muhamed Baljevic, MD

June 25th 2026

Drs Park and Baljevic discussed the evolution of myeloma management, including the integration of quadruplet therapies and bispecific antibodies.

D. Ross Camidge, MD, PhD; Mary (Nora) L. Disis, MD

How Strategic Focus Translates to Forward Momentum Across Cancer Immunology Frontiers: With D. Ross Camidge, MD, PhD; and Nora L. Disis, MD

ByRoss Camidge, MD, PhD,Mary L. (Nora) Disis, MD

June 24th 2026

Drs Camidge and Disis discuss Dr Disis’s evolution from a science-focused student to a global leader in cancer immunology.

Noa Biran, MD, breaks down key multiple myeloma data shared at the 2026 ASCO Annual Meeting.

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO)

ByNoa Biran, MD

June 23rd 2026

Noa Biran, MD, breaks down key multiple myeloma data shared at the 2026 ASCO Annual Meeting.

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

ByZev A. Wainberg, MD

June 19th 2026

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

ByBrad Haverkos, MD

June 18th 2026

Brad Haverkos, MD, discusses evolving management and treatment adherence strategies in cutaneous T-cell lymphoma.

Podcasts

Recent Episodes

All series

Oncology Unplugged With Dr Chandler Park

Pediatrics

Breast Cancer Briefing

Marvels in Medicine

One for Minutes With Markman

Talking Tumors

Ask Me Anything

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

OncLive on Air Powered by PER

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

DLBCL 2026 UPDATE

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

How a Passion for Translational Research Fuses Surgery, Science, and Phase 1 Drug Development: With D. Ross Camidge, MD, PhD; and Funda Meric-Bernstam, MD

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD

Unlocking the Power of ctDNA for Residual Disease, Resistance Monitoring, and Real-Time Treatment Decisions in GI Cancers: With Christopher Lieu, MD

FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Quadruplet Regimens and T-Cell Redirection Are on the Map of Myeloma Management Strategies: With Chandler Park, MD; Muhamed Baljevic, MD, FACP

How Strategic Focus Translates to Forward Momentum Across Cancer Immunology Frontiers: With D. Ross Camidge, MD, PhD; and Nora L. Disis, MD

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO)

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

CARiBOU Regimen Drives Complete Metabolic Responses in First-Line Mantle Cell Lymphoma

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC